Advertisement
U.S. markets closed

PHAXIAM Therapeutics S.A. (PHXM.PA)

Paris - Paris Delayed Price. Currency in EUR
1.5820-0.0140 (-0.88%)
As of 01:41PM CET. Market open.
Currency in EUR

Valuation Measures4

Market Cap (intraday) 15.98M
Enterprise Value -5.82M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)0.44
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA 1.80

Trading Information

Stock Price History

Beta (5Y Monthly) 1.82
52-Week Change 3-61.73%
S&P500 52-Week Change 331.33%
52 Week High 35.0000
52 Week Low 31.5000
50-Day Moving Average 31.7230
200-Day Moving Average 32.2807

Share Statistics

Avg Vol (3 month) 313.29k
Avg Vol (10 day) 324.31k
Shares Outstanding 510.01M
Implied Shares Outstanding 610.3M
Float 85.89M
% Held by Insiders 129.45%
% Held by Institutions 116.99%
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 20.1:1
Last Split Date 3Sep 18, 2023

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Jun 30, 2024

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-975.11%

Management Effectiveness

Return on Assets (ttm)N/A
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)2.14M
Revenue Per Share (ttm)0.28
Quarterly Revenue Growth (yoy)293.20%
Gross Profit (ttm)N/A
EBITDA -18.9M
Net Income Avi to Common (ttm)-21.92M
Diluted EPS (ttm)-0.9800
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)N/A
Total Cash Per Share (mrq)N/A
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)N/A
Book Value Per Share (mrq)4.22

Cash Flow Statement

Operating Cash Flow (ttm)N/A
Levered Free Cash Flow (ttm)N/A